1- or 3-Month DAPT in Patients With HBR With or Without Oral Anticoagulant Therapy After PCI.
Valgimigli M, Spirito A, Sartori S, Angiolillo DJ, Vranckx P, de la Torre Hernandez JM, Krucoff MW, Bangalore S, Bhatt DL, Campo G, Cao D, Chehab BM, Choi JW, Feng Y, Ge J, Hermiller J, Kunadian V, Lupo S, Makkar RR, Maksoud A, Neumann FJ, Picon H, Saito S, Sardella G, Thiele H, Toelg R, Varenne O, Vogel B, Zhou Y, Windecker S, Mehran R.
Valgimigli M, et al. Among authors: thiele h.
JACC Cardiovasc Interv. 2023 Oct 23;16(20):2498-2510. doi: 10.1016/j.jcin.2023.08.014. Epub 2023 Oct 4.
JACC Cardiovasc Interv. 2023.
PMID: 37804290
BACKGROUND: The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients on long-term oral anticoagulation (OAC) therapy is still uncertain. OBJECTIVES: The aim of this analysis was to assess the effects of 1- vs 3-mon …
BACKGROUND: The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients on long-t …